share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Mar 18 17:46
Summary by Moomoo AI
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more